CLBT logo

Cellebrite DI (CLBT) EBITDA

Annual EBITDA

$67.51 M
+$132.92 M+203.21%

December 31, 2024


Summary


Performance

CLBT EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCLBTprofitabilitymetrics:

Quarterly EBITDA

$18.46 M
-$3.61 M-16.36%

December 31, 2024


Summary


Performance

CLBT Quarterly EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCLBTprofitabilitymetrics:

TTM EBITDA

-$45.54 M
+$109.50 M+70.63%

December 31, 2024


Summary


Performance

CLBT TTM EBITDA Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherCLBTprofitabilitymetrics:

EBITDA Formula

EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization

CLBT EBITDA Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+203.2%+120.3%+30.4%
3 y3 years-24.5%+16.4%-128.9%
5 y5 years+1100.4%+16.4%-128.9%

CLBT EBITDA Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-48.1%+203.2%-86.0%+118.8%-128.9%+71.8%
5 y5-year-48.1%+203.2%-86.0%+118.8%-128.9%+71.8%
alltimeall time-48.1%+203.2%-86.0%+118.8%-128.9%+71.8%

Cellebrite DI EBITDA History

DateAnnualQuarterlyTTM
Dec 2024
$67.51 M(-203.2%)
$18.46 M(-16.4%)
-$45.54 M(-70.6%)
Sep 2024
-
$22.07 M(-122.5%)
-$155.04 M(-3.8%)
Jun 2024
-
-$97.99 M(-921.6%)
-$161.25 M(+187.6%)
Mar 2024
-
$11.93 M(-113.1%)
-$56.07 M(-14.3%)
Dec 2023
-$65.41 M(-150.3%)
-$91.05 M(-674.1%)
-$65.41 M(-141.5%)
Sep 2023
-
$15.86 M(+120.5%)
$157.69 M(+10.2%)
Jun 2023
-
$7.19 M(+178.4%)
$143.05 M(+7.9%)
Mar 2023
-
$2.58 M(-98.0%)
$132.52 M(+1.9%)
Dec 2022
$130.10 M
$132.06 M(>+9900.0%)
$130.10 M(+78.9%)
Sep 2022
-
$1.22 M(-136.5%)
$72.72 M(+3.1%)
DateAnnualQuarterlyTTM
Jun 2022
-
-$3.34 M(-2113.3%)
$70.50 M(-15.8%)
Mar 2022
-
$166.00 K(-99.8%)
$83.76 M(-6.4%)
Dec 2021
$89.47 M(+417.9%)
$74.67 M(-7604.7%)
$89.47 M(+279.5%)
Sep 2021
-
-$995.00 K(-110.0%)
$23.57 M(-33.1%)
Jun 2021
-
$9.92 M(+69.0%)
$35.24 M(+23.7%)
Mar 2021
-
$5.87 M(-33.2%)
$28.49 M(+25.9%)
Dec 2020
$17.28 M(+207.2%)
$8.78 M(-17.7%)
$22.62 M(+63.4%)
Sep 2020
-
$10.67 M(+236.5%)
$13.84 M(+336.5%)
Jun 2020
-
$3.17 M
$3.17 M
Dec 2019
$5.62 M
-
-

FAQ

  • What is Cellebrite DI annual EBITDA?
  • What is the all time high annual EBITDA for Cellebrite DI?
  • What is Cellebrite DI annual EBITDA year-on-year change?
  • What is Cellebrite DI quarterly EBITDA?
  • What is the all time high quarterly EBITDA for Cellebrite DI?
  • What is Cellebrite DI quarterly EBITDA year-on-year change?
  • What is Cellebrite DI TTM EBITDA?
  • What is the all time high TTM EBITDA for Cellebrite DI?
  • What is Cellebrite DI TTM EBITDA year-on-year change?

What is Cellebrite DI annual EBITDA?

The current annual EBITDA of CLBT is $67.51 M

What is the all time high annual EBITDA for Cellebrite DI?

Cellebrite DI all-time high annual EBITDA is $130.10 M

What is Cellebrite DI annual EBITDA year-on-year change?

Over the past year, CLBT annual EBITDA has changed by +$132.92 M (+203.21%)

What is Cellebrite DI quarterly EBITDA?

The current quarterly EBITDA of CLBT is $18.46 M

What is the all time high quarterly EBITDA for Cellebrite DI?

Cellebrite DI all-time high quarterly EBITDA is $132.06 M

What is Cellebrite DI quarterly EBITDA year-on-year change?

Over the past year, CLBT quarterly EBITDA has changed by +$109.50 M (+120.27%)

What is Cellebrite DI TTM EBITDA?

The current TTM EBITDA of CLBT is -$45.54 M

What is the all time high TTM EBITDA for Cellebrite DI?

Cellebrite DI all-time high TTM EBITDA is $157.69 M

What is Cellebrite DI TTM EBITDA year-on-year change?

Over the past year, CLBT TTM EBITDA has changed by +$19.87 M (+30.37%)